-
Critical Illness in Asia – Product Evolution and its Implications
By Orchis Li Apr 07, 2022 English
Highlights from the Gen Re Dread Disease Survey We started offering Critical Illness (CI) products in the late 1980s and early 1990s, covering just seven diseases. This quickly increased to around 30 conditions and then more than 50 by the late 1990s. In...
Read More -
The Gen Re Dread Disease Survey – Key Takeaways for the Hong Kong Market
By Orchis Li Dec 16, 2021 English
Our 8th survey of Dread Disease insurance in Asia covers the experience in China, Hong Kong, Malaysia and Singapore from 2015 to 2019. While we had originally planned to complete our data collection for the new report by Q3 of 2020, COVID‑19 hit hard...
Read More -
China’s Healthcare Market Is Booming, With Ecosystems Taking Shape
By Ning Qing and Boyuan Qiu Aug 10, 2021 English
With a compound annual insurance premium growth rate of over 30% for six consecutive years, RMB817.3 billion-worth of premium recorded for 2020 and RMB2 trillion anticipated for 2025, the health insurance market in China continues to outpace all other...
Read More -
Series: Risk InsightsLiquid Biopsy and the Early Diagnosis of Cancer
Issue: Nov 02, 2020 Critical Illness English
In recent years, the primary tool for early diagnosis of cancer has been liquid biopsy (a blood test), but it remains complex, costly and time-consuming to fully screen for all mutations.
Read More
